Global Immune Checkpoint Inhibitors

Global Immune Checkpoint Inhibitors Market Research Report: (2022-2027)

By Drug Class (PD- 1 (Opdivo (Nivolumab), Keytruda (Pembrolizumab)), PD- L1 (Tecentriq (Atezolizumab), Bavencio (Avelumab), Imfinzi (Durvalumab), CTLA- 4 (Yervoy (Ipilimumab)), By Application (Melanom Read more

  • Healthcare
  • Jun 2022
  • 198
  • HC22091

Market Definition

One of the prominent roles of a body's immune system is its ability to differentiate between normal cells and foreign cells like bacteria, viruses, germs, & even cancer cells. The immune system uses checkpoint proteins on the immune cells to attack the foreign cells without affecting the normal ones. The checkpoints behave like switches that turn on or off a response.

However, sometimes the cancer cells outwit the immune system and spread in the body. It is where immune checkpoint inhibitors come into the picture, where they use the body's immune system and turn it on to target the cancer cells. These inhibitors are known for attacking potentially harmful agents. In the case where immune response begins affecting healthy tissues, the system can be turned off in order to prevent the damage.

While immune checkpoint inhibitors do not kill the cancer cells directly, they find ways to help the immune system find & attack the cells throughout the body. With rapid advancements in checkpoint inhibitors, these proteins can now also be used for the treatment of a few cancers by infusing drugs into the vein.

Market Insights

The Global Immune Checkpoint Inhibitors Market is projected to grow at a CAGR of around 17% during the forecast period, i.e., 2022-27. The growth of the market would be driven primarily by the rapidly increasing incidence of cancer worldwide & the mounting demand for effective & safe treatments, i.e., instigating governments to enhance the healthcare infrastructure to cater to the high unmet patient needs. 

Report Coverage Details
Study Period Historical Data: 2017-20
Base Year: 2021
Forecast Period: 2022-27
CAGR (2022-2027) 17%
Regions Covered North America: The US, Canada, Mexico
Europe: Germany, The UK, Germany, France, Italy, Spain, Rest of Europe
Asia-Pacific: China, Japan, India, Australia, South East Asia, Rest of Asia-Pacific
South America: Brazil, Rest of Latin America
Middle East & Africa: South Africa, GCC, Rest of Middle East & Africa
Key Companies Profiled

AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bluebird Bio, Inc., Bristol Myers Squibb, CARsgen Therapeutics, Eli Lilly and Company, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Others

Unit Denominations USD Million/Billion

 

In addition, since the advent of immune checkpoint inhibitors, cancer treatment has witnessed a revolution in the past years and even demonstrated alternation in outcomes for various cancers, including Malignant Melanoma & Non-Small Cell Lung Cancer. This aspect is playing a prominent role in instigating the leading biopharma companies to conduct rigorous research & development activities to bring innovations in immune checkpoint inhibitors and introduce novel drugs for greater efficacy & safety.

Besides, the growing adoption of immune checkpoint inhibitors for preventing cancer cells from turning off T lymphocytes (T cells) is also elevating their demand and augmenting the overall market growth. T cells are a kind of immune system cells that kill cancer and have receptors on their surfaces from where other cells stick & turn them on or off. In some cases, the cancer cells bind with the receptors on activated T cells and turn them off. However, immune checkpoint inhibitors prevent the cancer cells from doing so & allow T cells to infiltrate the tumor while eliminating its growth. Hence, due to such benefits, the demand for immune checkpoint inhibitors is rising rapidly for their application in various cancer treatments and stimulating the expansion of the global market. 

Moreover, growing awareness among patients about their benefits, like fewer side effects & targeted therapeutic effects, is another prominent aspect contributing to the mounting demand for immune checkpoint inhibitors worldwide. It, in turn, is also attracting massive funding from various pharmaceuticals, biotech companies, universities, & cancer centers in the research & development of more effective immune checkpoint inhibitors and fueling the overall market growth.

  1. Introduction
    1. Research Process
    2. Assumption
    3. Market Segmentation
    4. Market Definition
  2. Executive Summary
  3. Global Immune Checkpoint Inhibitors Market Trends & Insights
  4. Global Immune Checkpoint Inhibitors Market Regulation & Policy, By Country
  5. Global Immune Checkpoint Inhibitors Market Dynamics
    1. Growth Drivers
    2. Challenges
    3. Impact Analysis
  6. Global Immune Checkpoint Inhibitors Market Hotspot and Opportunities
  7. Global Immune Checkpoint Inhibitors Market Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
        1. PD- 1
          1. Opdivo (Nivolumab)
          2. Keytruda (Pembrolizumab)
        2. PD- L1
          1. Tecentriq (Atezolizumab)
          2. Bavencio (Avelumab)
          3. Imfinzi (Durvalumab)
        3. CTLA- 4
          1. Yervoy (Ipilimumab)
      2. By Application
        1. Melanoma
        2. Hodgkin Lymphoma
        3. Renal Cell Cancer
        4. Urothelial Cancer
        5. Non-Small Cell Lung Cancer (NSCLC)
        6. Others (Head & Neck Cancers, etc.)
      3. By End-User
        1. Hospitals
        2. Clinics
        3. Specialty Cancer Centers
      4. By Region
        1. North America
        2. South America
        3. Europe
        4. Middle East & Africa
        5. Asia-Pacific
      5. By Company
        1. Competition Characteristics
        2. Revenue Shares
        3. Competitor Placement in MarkNtel Advisor’s Quadrant
  8. North America Immune Checkpoint Inhibitors Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. The US
        2. Canada
        3. Mexico
  9. South America Immune Checkpoint Inhibitors Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. Brazil
        2. Rest of Latin America
  10. Europe Immune Checkpoint Inhibitors Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. The UK
        2. Germany
        3. France
        4. Italy
        5. Spain
        6. Rest of Europe
  11. Middle East & Africa Immune Checkpoint Inhibitors Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. South Africa
        2. GCC
        3. Rest of Middle East & Africa
  12. Asia-Pacific Immune Checkpoint Inhibitors Outlook, 2017- 2027
    1. Market Size and Analysis
      1. By Revenues in USD Million
    2. Market Share and Analysis
      1. By Drug Class
      2. By Application
      3. By End-User
      4. By Country
        1. China
        2. Japan
        3. India
        4. Australia
        5. South East Asia
        6. Rest of Asia Pacific
  13. Global Immune Checkpoint Inhibitors Market Key Strategic Imperatives for Success and Growth
  14. Competitive Outlook
    1. Competition Matrix
      1. By Application Portfolio
      2. Brand Specialization
      3. Target Markets
      4. Target by Applications
      5. Research & Development
      6. Strategic Alliances
      7. Strategic Initiatives
    2. Company Profiles (Business Description, By Application Segments, Business Segments, Financials, Strategic Alliances/ Partnerships, Future Plans)
      1. AbbVie Inc.
      2. Amgen Inc.
      3. AstraZeneca PLC
      4. Bluebird Bio, Inc.
      5. Bristol Myers Squibb
      6. CARsgen Therapeutics
      7. Eli Lilly and Company
      8. GlaxoSmithKline PLC
      9. Merck & Co., Inc.
      10. Novartis International AG
      11. Pfizer Inc.
      12. Regeneron Pharmaceuticals Inc.
      13. Sanofi S.A.
      14. Sun Pharmaceutical Industries Ltd.
      15. Others
  15. Disclaimer
 Immune Checkpoint Inhibitors Market Segmentation
*This field is required